Envoy Medical, Inc. (COCH) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc.
Analysis Summary
Trailing-twelve-month margins: gross margin -385.5%, operating margin -114.1%, net margin -113.0%.
At the current price of $0.71, COCH has negative trailing earnings (P/E not meaningful) and an ROE of 17.20%. Market capitalisation stands at $15M.
Balance sheet quality for COCH: current ratio of 0.5, net cash position of $2.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.71 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 21.90 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1719.71% |
| Return on Invested Capital | -206.35% |
| Return on Assets | -97.71% |
| Gross Margin | -385.51% |
| Operating Margin | -11411.11% |
| Net Margin | -11304.83% |
Financial Health
| Debt / Equity | 0.25 |
| Current Ratio | 1.73 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| COCH | Envoy Medical, Inc. | $15M | 21.90 | 17.2% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -3.90% |
| 3 months | +12.00% |
| Year-to-date | +7.41% |
| 1 year | -46.20% |
| 3 years | -93.20% |
| 5 years | -92.66% |
52-Week Range
| 52-week High | $1.89 |
| 52-week Low | $0.36 |
| Avg Volume (90d) | 296K |
Related companies: ADGM · ADTX · ALUR · ATHA · CODX · HCTI · IRIX
Explore sector: Healthcare · Medical - Devices
More sections of COCH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks